| ★ |  2024 DPRP Standards - Revisions to the DPRP Portal and Data Submission Process Webinar | Centers for Disease Control and Prevention (CDC) @cdc | 595 | Estados Unidos | |
| 18 |  Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS | | 4.3K | Estados Unidos | 84 |
| 2 |  Lifestyle Coach Requirements and Responsibilities Webinar | Centers for Disease Control and Prevention (CDC) @cdc | 1.1K | Estados Unidos | 90 |
| 1 |  Understanding the DPRP Evaluation Report | Centers for Disease Control and Prevention (CDC) @cdc | 1.0K | Estados Unidos | 93 |
| 3 |  Diabetes Dialogue: The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD | | 584 | Estados Unidos | 86 |
| 13 |  GDF2026 - Common Manufacturing Deficiencies for Complex Dosage Forms | U.S. Food and Drug Administration @us_fda | 425 | Estados Unidos | 85 |
| 17 |  GDF2026 - Q&A Discussion Panel Four and Day One Closing | U.S. Food and Drug Administration @us_fda | 187 | Estados Unidos | 84 |
| 16 |  Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 84 |
| 11 |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 85 |
| 20 |  Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 84 |
| 5 |  Diabetes Dialogue: Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS | | 94 | Estados Unidos | 85 |
| 6 |  Diabetes Dialogue: The International Diabetes Federation and Care in India, With Amit Gupta, MBBS | | 79 | Estados Unidos | 85 |
| 9 |  Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 85 |
| 19 |  Disparities in Place of Care by Race and Ethnicity among Medicaid Beneficiaries with Diabetes | | 67 | Estados Unidos | 84 |
| 12 |  Webinar | Fundación Preven A.C. @preven_ac | 60 | México | 85 |
| 7 |  Les inhibiteurs de la DPP4. | | 54 | Francia | 85 |
| 8 |  Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients | | 53 | Estados Unidos | 85 |
| 4 |  GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | 85 |
| 14 |  Les analogues du GLP1. | | 30 | Francia | 85 |
| 10 |  Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 85 |
| 15 |  Webinar sobre el IPNR y certificación | Centro Español de Plásticos @cepplasticos | 0 | España | 85 |